Health Affairs January 7, 2026
Editor’s Note
This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation. Articles in this topic offer timely analysis of regulatory, legislative, and judicial developments in health policy under the Trump-Vance Administration and the 119th Congress.
This past year featured significant developments in prescription drug policy, most notably the continued implementation of Biden-era drug pricing reforms and changes made by the new Trump Administration.
In this article, I review five key developments from the past year and offer five items to watch in 2026.
Looking Back: 2025
Developments in 2025 focused largely on executive action, both to implement previously...
Today's Sponsors
Today's Sponsor